MetaCap

Bright Minds Biosciences (DRUG) vs Yarrow Bioscience (YARW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Yarrow Bioscience (YARW) has outperformed Bright Minds Biosciences (DRUG) over the past year, losing 26.7% versus a loss of 65.2%. Over five years, DRUG leads with a -7.3% price change compared with -98.6% for YARW. Bright Minds Biosciences is the larger company by market cap ($201.2 million vs $196.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DRUG-65.18%YARW-26.70%
+174%+47%-79%
Nov 21, 20251 yearNov 20, 2026
DRUG-18.73%YARW-98.66%
+276%+80%-117%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DRUG versus YARW key metrics
MetricDRUGYARW
Share price$20.40$12.90
Market cap$201.23M$196.53M
1-day change-1.45%-9.35%
YTD return-73.86%-55.52%
1-year return-65.18%-26.70%
5-year return-7.27%-98.61%
EPS (TTM)$-2.05—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$570.00K
Revenue growth (YoY)—+13.77%
Net income (latest FY)—$-26.48M
Operating margin—-5219.12%
Net margin—-4646.14%
52-week high$123.75$46.95
52-week low$17.40$12.39
Distance from 52-week high-83.52%-72.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+426.18%+310.85%
Average volume173.24K153.34K
Shares outstanding9.86M15.23M
Employees267
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • YARW has outperformed DRUG by 38.5 percentage points over the past year.

About Bright Minds Biosciences

DRUG stock →

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

About Yarrow Bioscience

YARW stock →

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

DRUG vs YARW FAQ

Which is bigger, Bright Minds Biosciences or Yarrow Bioscience?

Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $201.23M compared with $196.53M for Yarrow Bioscience (YARW).

Which stock has performed better over the past year, DRUG or YARW?

YARW returned -26.70% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.

Are Bright Minds Biosciences and Yarrow Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons